Morgan Stanley, JPMorgan IPO deal filing nixed in Hong Kong
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[HONG KONG] Morgan Stanley and JPMorgan Chase & Co's application to take a Chinese biotechnology company public was rejected by the Hong Kong stock exchange.
The announcement about Akeso Inc's listing, made late Wednesday, puts the Wall Street banks on a list that bankers have dubbed "name and shame" because it discloses the financial institutions and companies involved in any failed application.
Hong Kong Exchanges & Clearing Ltd (HKEX) said in its statement that the IPO (initial public offering) application had been returned on Dec 5. It didn't provide a reason.
In a policy put in place in October 2013, IPO applications that are incomplete will be returned by HKEX. There's no tangible punishment for banks, but the company has to wait at least eight weeks to re-submit an IPO application.
Spokesmen at Morgan Stanley, JPMorgan and HKEX all declined to comment.
The bourse has rejected 21 applications to both its main board and its GEM market since 2014. Among past rejections, most are local and mainland Chinese banks, such as Guotai Junan Capital Ltd and Bocom International (Asia) Ltd. JPMorgan also made the list for a deal in 2016.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
Even if a bank is put on the list multiple times, there are few signs it undermines its ability to sponsor deals in the world's busiest IPO market. China Everbright Capital Ltd, for example, has also made the list twice.
BLOOMBERG
Share with us your feedback on BT's products and services
TRENDING NOW
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
